Cell therapies, such as CAR-T cells, are increasingly important for the treatment of cancer and other maladies. Production of such therapies involves a series of time-intensive steps that have been translated from cell biology laboratory-based procedures. This proposal aims to produce innovative modular technologies for the production of cell therapies with improved scalability and enhanced consistency and efficacy.
The University of Delaware and team aim to develop innovative modular technologies to produce cell therapies with improved scalability, enhanced consistency and efficacy, and the potential for reduced cost.
A prototype technology recently was established that integrates scalable, functionalized soft membranes into a flow-based device for enhancing T cell transduction and promoting T cell activation (completed PC3.1-132).
This work (PC5.2T-108) will build from this successful prototype to address more processing steps and other cell therapies, facilitated by the growth of our academic-industrial partnerships.
Establish workflows for enhancing the transduction of difficult-to-transduce cell types
Establish functionalities and workflows for cost-effective, short-term rapid T-cell processing steps.
Demonstrate devices for longer-term T-cell processing steps including closed-loop phenotype selection, activation, expansion, and transduction
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
University of Delaware
Agilent
EMD Millipore Corporation
